- Reaction score
- 133
I realize the scenarios are quite different, but consider how both pathogens and and cancer respond to our current therapies. With tuberculosis if we use simple mono therapy then we select for bacteria that are resistant and it ends up harder to treat, so we use RIPE therapy that is much more effective. Same principle with HAART therapy and HIV.
With Acute lymphocytic leukemia giving prednisone mono therapy prior to our modern day chemo regimens (built around prednisone) then we actually worsen overall prognosis and response to treatment.
I feel I see a similar phenomenon with hairloss... most try one therapy at a time and add on if there is no success. What if someone failed with fina and instead of moving to just duta they added on duta+seti. Or maybe even duta+seti+ru, maybe even something crazy like cpa or estrogen... would it be easier or harder for our hair follicles to reach a hairloss homeostasis?
With Acute lymphocytic leukemia giving prednisone mono therapy prior to our modern day chemo regimens (built around prednisone) then we actually worsen overall prognosis and response to treatment.
I feel I see a similar phenomenon with hairloss... most try one therapy at a time and add on if there is no success. What if someone failed with fina and instead of moving to just duta they added on duta+seti. Or maybe even duta+seti+ru, maybe even something crazy like cpa or estrogen... would it be easier or harder for our hair follicles to reach a hairloss homeostasis?
